City
Epaper

BHU wants clinical trial of drug to cure COVID-19

By IANS | Updated: April 24, 2020 16:55 IST

The Banaras Hindu University (BHU) wants to carry out a clinical trial of immunity-boosting ayurvedic drug 'Fifatrol' to check its efficacy in tackling the deadly COVID-19.

Open in App

Varanasi, April 24 The Banaras Hindu University (BHU) wants to carry out a clinical trial of immunity-boosting ayurvedic drug 'Fifatrol' to check its efficacy in tackling the deadly COVID-19.

However, the proposal is yet to be approved, official sources said.

According to BHU professor and principal investigator for the proposed project, Dr K N Dwivedi, the plan has been sent to a task force formed by the government for scientific validation of Ayurveda and traditional medicinal formulas through research institutions in tackling COVID-19.

The inter-disciplinary AYUSH Research and Development Task Force has members from the Department of Biotechnology (DBT), Council of Scientific and Industrial Research (CSIR) and also AYUSH practitioners and others.

The scientists are trying to identify potential preventive therapy and therapeutic approaches from AYUSH systems in different stages of COVID-19 treatment.

The AYUSH ministry had sought suggestions on various therapies, through a notification on March 31. The ministry asked Ayurveda, Yoga and naturopathy, Unani, Siddha and Homoeopathy (AYUSH) practitioners and institutions to submit their suggestions on various therapies, and has received over 2,000 proposals.

According to experts, "Fifatrol, enriched with immune-enhancing herbs, has been found to be effective in curing major bacterial infections such as staphylococcus species that causes fever, cough and cold, and skin diseases among others.

AIMIL Pharmaceuticals, the company that produces Fifatrol, said that drug is used to treat flu and viral infections of upper respiratory tract. But this is for the first time that experts have decided to determine if it can be helpful in combating the novel coronavirus.

Dr Dwivedi, who is the head of the Department of Dravyaguna at BHU, said Fifatrol is given to patients with symptoms similar to COVID-19.

"We are now trying to evaluate this drug on critically-ill COVID-19 patients to check if it can help reduce mortality," he said.

He said that during a trial on dengue patients at AIIMS, Bhopal, the drug was found to have increased platelet count significantly. The study also established that Fifatrol can strengthen the liver with no systemic side effects. Fifatrol is an anti-microbial solution prepared from 13 key herbs including sudarshan vati, sanjeevani vati, godanti bhasma, tribhuvan kirti ras and mrityunjay ras, tulsi, kutki, chirayata, motha and giloy.

( With inputs from IANS )

Tags: Ayush research and development task forceBanaras Hindu University
Open in App

Related Stories

NationalBHU Study: Black Carbon in Varanasi Sees Steady Decline Since 2012

HealthAfter Covishield, BHU Study Reveals Side Effects of Covaxin; Including Hair Loss, Skin Issues, and Menstrual Irregularities

NationalIIT-BHU Rape case: Three accused arrested, motorcycle seized

NationalPak farmer seeks rice seeds from BHU

HealthAyurveda medicines act faster: BHU study

Health Realted Stories

HealthScientists find cellular culprit behind age-related abdominal fat

HealthArmy Hospital performs its first minimally invasive glaucoma surgery

HealthScreening for both active and dormant TB infection key to improve detection: Study

HealthMinister Ashish Sood outlines plan to make Delhi a 'credible medical destination'

HealthIndia reduced poverty levels with targeted welfare schemes, economic reforms: World Bank